Is Compounded Semaglutide Still Legal in 2026?
Short answer: yes, but the ground has shifted twice in eighteen months and is shifting again. If you are on compounded medication - or about to prepay a year of it - this is the context nobody selling it to you is going to lead with.
Last updated: August 3, 2026
Quick Answer
Compounded semaglutide and tirzepatide remain legally available in 2026, but only through a much narrower route than in 2024. The wide-open path - mass compounding of what were essentially copies of the brand-name drugs - closed when the FDA declared both shortages resolved.
What remains is 503A compounding: state-licensed pharmacies preparing patient-specific medication against an individual prescription. Stanford Medicine's summary is that smaller 503A pharmacies, which compound for individual patients based on a prescription, would still be legally permitted to make patient-specific preparations.
The current pressure point: on 30 April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them. Public comments closed 29 June 2026. As of this writing the proposal is pending finalization - check the Federal Register docket for the current status before making decisions that depend on it.
The One-Sentence Version
Do not prepay twelve months for compounded GLP-1 medication without a written answer to this question: "If compounded semaglutide or tirzepatide becomes unavailable during my term, do I receive a refund for the unused portion, a substitute product, or neither?"
The Complete Timeline
Read the shape of that timeline, not just the dates. Every step has moved in one direction over eighteen months. Nothing here suggests the trend reverses, and planning as though it might is how people end up with a year prepaid on a product that becomes hard to get.
503A vs 503B: The Distinction That Decides Everything
Almost every confusing headline about compounded GLP-1s becomes clear once you know which of these two things it is talking about. They are different legal categories under the Federal Food, Drug, and Cosmetic Act.
| 503A | 503B | |
|---|---|---|
| What it is | Traditional state-licensed compounding pharmacy | Outsourcing facility registered with the FDA |
| Who it compounds for | Individual patients, against a specific prescription | Can produce in bulk without patient-specific prescriptions |
| Oversight | Primarily state boards of pharmacy | FDA inspection; must follow CGMP |
| Scale | Smaller | Large - supplies clinics and telehealth at volume |
| The April 2026 proposal | Not directly targeted | Directly targeted - the bulks list is a 503B mechanism |
This is why "is it banned?" has no single answer. The proposal aims at the 503B route - the one that supplies large telehealth operations at volume. 503A patient-specific compounding sits on a different legal footing and, per Stanford Medicine, would still be permitted.
The practical consequence for you: the 503B route is the one that makes $99/month pricing possible, because volume is what drives cost down. If it closes, the economics of the cheapest programs change - even though compounding itself continues. That is the risk you are carrying when you prepay.
The April 2026 Proposal
On 30 April 2026, the FDA published a Federal Register notice identifying three bulk drug substances it proposes not to include on the 503B Bulks List: semaglutide, tirzepatide and liraglutide.
The stated basis is no clinical need for outsourcing facilities to compound them - which follows logically from the shortages being resolved. When the approved products are available, the argument for a bulk-compounded alternative weakens considerably.
Public comments were invited through 29 June 2026. Pharmacy Times characterized the move as the FDA seeking to permanently close the door on compounded GLP-1s.
An honest limit on this article: we can tell you the proposal was made and the comment period closed. We cannot tell you the final outcome, because a proposal is not a final rule and the process takes time. Before acting on anything here, check the Federal Register docket directly for the current status - and treat any provider that tells you the matter is settled, in either direction, with caution.
"Personalized Dosing" and Its Limits
You may notice compounded GLP-1s marketed with unusual dose strengths, or bundled with vitamin B12, or described as "personalized" or "customized." This is not a stylistic choice.
Compounding law generally does not permit making a drug that is essentially a copy of a commercially available approved product. Once the approved drugs are available, a straight copy is on difficult ground. A preparation that differs meaningfully - a different strength, an added ingredient - is argued to fall outside that prohibition and to serve a clinical need the approved product does not.
Two things to understand about this:
- It can be entirely legitimate. Real patients genuinely need doses or formulations the manufacturer does not make - that is what compounding exists for, and has for a very long time.
- It can also be a workaround dressed as a clinical rationale. The FDA's April 2026 reminder that certain conditions must be met for the 503A and 503B exemptions to apply is aimed squarely at this.
How to tell which you are looking at: ask why your formulation is right for you specifically. A clinician who can explain the clinical reasoning for your dose or the added ingredient is compounding. One who cannot, or who gives the same answer to every patient, is describing a business model. Adding B12 to everyone's semaglutide is not personalization.
The 25 Warning Letters
Separately from the compounding rules, the FDA issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products.
This is a distinct issue and worth separating clearly: it concerns how products are marketed, not whether compounding itself is permitted. But it tells you something useful about the category - that regulators found misleading claims widespread enough to act at scale.
Claims worth treating sceptically when you encounter them:
- "FDA-approved" applied to a compounded product. Compounded medications are not FDA-approved. A pharmacy can be licensed and inspected; the preparation is still not an approved drug.
- "Same as Ozempic/Zepbound." Same active ingredient is not the same product - manufacturing standards, testing and consistency differ.
- Trial results presented as the compounded product's own. STEP and SURMOUNT studied the approved drugs.
- Any suggestion the regulatory picture is settled. It is not.
Our reviews of Trimi, Fridays and FormBlends each apply this lens to a specific provider.
What to Do, by Situation
You are currently on compounded medication and it is working
Do not stop, and do not panic - nothing here makes your current medication unsafe or illegal. Do two things: ask your provider what their plan is if supply is disrupted, and ask your prescriber what transitioning to an approved product would look like for you. Having that conversation now is far better than having it the week your refill does not arrive.
You are considering an annual prepay plan
Get the refund terms in writing first, specifically for the scenario where compounded medication becomes unavailable mid-term. If the answer is unclear, take the month-to-month rate instead. The discount on annual plans is typically 40-50%, which is genuinely significant - but you are buying it with twelve months of exposure to a regulatory process actively moving against the product.
You are choosing between compounded and brand-name
Run the numbers again, because the gap has narrowed sharply. Brand-name self-pay pricing has fallen - Ozempic tablets are $149 at the starting dose and $299 at maintenance, and Wegovy injections around $349. When compounded pricing approaches those figures, the main argument for compounding is gone. See our Ozempic pill cost guide and cash-pay comparison.
You have insurance you have not checked
Check it before anything else. Ask specifically whether semaglutide or tirzepatide is covered for your indication - coverage for diabetes and coverage for weight management are separate decisions on most plans. A covered prescription beats every cash-pay route, compounded or not.
Questions to Ask Your Provider
None of these are confrontational, and a provider's willingness to answer them plainly is itself the most useful signal you will get.
- Which pharmacy fills my prescription, is it 503A or 503B, and which state licenses it? Then verify that licence with the state board yourself - it takes a few minutes.
- Is my preparation patient-specific, or produced in bulk? This determines which set of rules applies to you.
- What is the clinical reason for my specific dose or added ingredients? A real answer is specific to you.
- Is there third-party potency and sterility testing for my formulation? Ask to see it.
- If compounded supply is disrupted during my term, what happens - refund, substitute, or neither? In writing.
- What would transitioning me to an approved product look like? A provider with no answer has not thought about your continuity of care.
Our compounding pharmacy guide goes deeper on evaluating sourcing and testing.
Want to Avoid the Prepay Exposure Entirely?
The regulatory risk here is concentrated in long commitments. Coreage Rx bundles medication, provider oversight and support into one all-inclusive monthly price with no twelve-month lock-in.
See Coreage Rx Pricing →Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Yes, but through a narrower route than in 2024. Mass compounding of essentially copies of the approved drugs ended when the FDA declared the shortages resolved - tirzepatide in December 2024 and semaglutide in February 2025. What remains is primarily 503A patient-specific compounding by state-licensed pharmacies against an individual prescription, which per Stanford Medicine would still be permitted.
Has compounded tirzepatide been banned?
No. The FDA proposed on 30 April 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, and comments closed 29 June 2026 - but a proposal is not a final rule, and the 503B bulks list governs bulk outsourcing facilities rather than all compounding. Patient-specific 503A compounding sits on different footing. Check the Federal Register docket for current status.
What is the difference between 503A and 503B?
503A pharmacies are traditional state-licensed compounders preparing medication for individual patients against a specific prescription, overseen primarily by state boards. 503B outsourcing facilities register with the FDA, follow CGMP, are FDA-inspected, and can produce in bulk without patient-specific prescriptions. The April 2026 proposal targets the 503B route - which is the one that makes very low pricing possible, because volume drives cost down.
Should I stop taking my compounded medication?
No - nothing in the regulatory situation makes medication you are currently taking unsafe, and stopping a GLP-1 abruptly has its own consequences. Do ask your provider what happens if supply is disrupted, and ask your prescriber what a transition to an approved product would involve. Have that conversation now rather than the week a refill fails to arrive.
Why do compounded GLP-1s come with B12 or unusual doses?
Compounding law generally does not permit making a drug that is essentially a copy of an available approved product. A preparation that differs meaningfully - a different strength or an added ingredient - is argued to fall outside that prohibition. Sometimes that reflects genuine clinical need, which is what compounding exists for. Sometimes it is a workaround with clinical language attached. Ask why your specific formulation suits you; a clinician who can explain it for you personally is compounding, one who gives every patient the same answer is describing a business model.
Is compounded medication FDA-approved?
No, and any provider telling you otherwise is making a claim the FDA has acted against - it issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Compounded medications are not FDA-approved and are not evaluated by the FDA for safety, effectiveness or quality. A pharmacy can be licensed and inspected while the preparation itself remains unapproved.
Should I take an annual plan to get the lowest price?
Only with written refund terms covering the scenario where compounded medication becomes unavailable mid-term, and only if you have already tolerated a GLP-1. Annual discounts run 40-50%, which is real money - but you are buying it with twelve months of exposure to a regulatory process that has moved in one direction for eighteen months. The month-to-month rate is the price of keeping your options.
Is brand-name now cheap enough to switch?
Increasingly, yes - run the comparison again if you last checked in 2024. Ozempic tablets are $149 at the starting dose and $299 at maintenance, and Wegovy injections around $349, against typical compounded pricing of $150-$300 for semaglutide. When the gap narrows to nothing, you are taking on regulatory and manufacturing-standard risk for no saving.
Medical and Regulatory Disclaimer
This article is for informational purposes only and constitutes neither medical nor legal advice. Regulatory status described here reflects publicly available information at the time of writing; the 30 April 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list had a comment period closing 29 June 2026 and, as of this writing, was pending finalization - a proposal is not a final rule, and the position may have changed. Verify current status via the Federal Register and FDA.gov before making decisions that depend on it. Compounded medications are not FDA-approved and are not evaluated by the FDA for safety, effectiveness or quality. Nothing here should be read as an instruction to start or stop any medication; always consult a qualified healthcare provider. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer.